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encephalitis
ABSTRACT
Objective: To assess structural and functional changes in the afferent visual system following
anti-NMDA receptor (NMDAR) encephalitis.
Methods: In this cross-sectional study including 31 patients after acute NMDAR encephalitis and
matched healthy controls, visual function was assessed as high-contrast visual acuity using Early
Treatment Diabetic Retinopathy Study charts and low-contrast sensitivity using Functional Acu-
ity Contrast Test. Retinal changes were measured using optical coherence tomography with
assessment of peripapillary retinal nerve fiber layer (pRNFL) and macular intraretinal layer thick-
nesses. Residual clinical impairment was described using the modified Rankin Scale.
Results: High-contrast (logMAR 0.02 6 0.14 vs 20.09 6 0.14, p , 0.001) and low-contrast
(area under the curve 1.89 6 0.21 vs 2.00 6 0.26, p 5 0.039) visual acuity were reduced in
patients in comparison to healthy controls. More severely affected patients performed worse in
visual acuity testing than patients with good recovery (logMAR 20.02 6 0.11 vs 0.08 6 0.17,
p 5 0.030). In contrast, patients did not differ from matched healthy controls in pRNFL or in
thickness of intraretinal layers, including the ganglion cell complex, the inner nuclear layer, the
outer nuclear and plexiform layers, and the photoreceptor layer.
Conclusions: After acute NMDAR encephalitis, patients have mild visual dysfunction in compari-
son to matched healthy controls, while retinal structure appears unaltered. These observations
could point to an impairment of anterior or posterior visual pathway NMDAR function that is sim-
ilar to dysfunction of NMDAR in cerebral cortex and subcortical structures. Alternatively, residual
cognitive impairment might reduce visual function. Neurol Neuroimmunol Neuroinflamm 2016;3:
e198; doi: 10.1212/NXI.0000000000000198
GLOSSARY
AQP4 5 aquaporin-4; AUC 5 area under the curve; ETDRS 5 Early Treatment Diabetic Retinopathy Study; FACT 5 Func-
tional Acuity Contrast Test; GCC5 ganglion cell complex; GEE 5 generalized estimating equation; IgG 5 immunoglobulin G;
INL 5 inner nuclear layer; MOG 5 myelin oligodendrocyte glycoprotein; mRS 5 modified Rankin Scale; NMDAR 5 NMDA
receptor; OCT 5 optical coherence tomography; OPNL 5 outer plexiform and nuclear layer; PRL 5 photoreceptor layer;
pRNFL 5 peripapillary retinal nerve fiber layer; VA 5 visual acuity.
Anti-NMDA receptor (NMDAR) encephalitis is an acute disorder of the CNS caused by anti-
bodies against the extracellular N-terminal domain of the receptor’s NR1 subunit.1–3 Patients
develop a severe neuropsychiatric syndrome with amnesia, behavioral changes, psychosis, dys-
kinesia, and epileptic seizures, and may also have hypoventilation and decreased consciousness.4
Eighty percent of patients recover well, achieving modified Rankin Scale (mRS) scores between
0 and 2, although many patients continue to have cognitive deficits, mostly in the form of
memory and executive function impairment.5,6 MRI appears normal in 25%–50% of patients
with acute NMDAR encephalitis, but can show mild and transient T2/fluid-attenuated inver-
sion recovery hyperintensities in the hippocampus, brainstem, and cerebral white and gray
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matter.7 In contrast, lasting functional and
white matter brain changes, as well as persist-
ing hippocampal damage associated with
memory impairment, were observed recently
in patients recovering from NMDAR
encephalitis.8,9
Retinal neurons express NMDAR, which
are—among others—relevant for contrast sen-
sitivity,10 and might be potential targets in
acute NMDAR encephalitis. Specifically,
mRNA for NMDAR subunits or functional
NMDAR expression have been shown in hor-
izontal cells,11,12 amacrine cells,13–16 and gan-
glion cells in several vertebrates.13,14,17–22
Visual dysfunction is not among the common
symptoms of acute NMDAR encephalitis;
however, given the frequently severe presenta-
tion, visual symptoms might not attract atten-
tion or might be difficult to assess during
the acute disease stage. Moreover, an overlap
with demyelinating syndromes was recently
described in a subgroup of patients with
NMDAR encephalitis, many of them with
visual deficits that were mostly caused by optic
neuritis.23,24 The objective of this study was to
investigate the retina for potential structural
damage after NMDAR encephalitis as well as
potential visual function changes.
METHODS Patients and controls. For this cross-sectional
observational study, patients post-recovery from the acute
disease stage of NMDAR encephalitis were recruited from the
outpatient clinic of the Department of Neurology of Charité-
Universitätsmedizin Berlin. Inclusion criteria were diagnosis of
previous NMDAR encephalitis and ability to give informed
consent. Diagnosis was based on immunoglobulin G (IgG)
NMDAR antibodies in patients’ CSF and characteristic clinical
presentation. Residual clinical impairment was evaluated using
the mRS.25 Two patients presented with a demyelinating
overlap syndrome; both tested seronegative for aquaporin-4
(AQP4) and myelin oligodendrocyte glycoprotein (MOG)
antibodies. Twenty-five patients had been included in previous
studies investigating functional and structural MRI changes.8,9
Healthy controls were randomly selected from the NeuroCure
Clinical Research Center’s research database and matched for age
and sex.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the internal ethics review
board of the Charité-Universitätsmedizin Berlin and was con-
ducted in conformity with the 1954 Declaration of Helsinki in
its currently applicable version. All study participants gave
informed written consent.
Visual function. Visual function testing was performed with
Optec 6500 (Stereo Optical Inc., Chicago, IL). High-contrast
visual acuity (VA) was measured using Early Treatment
Diabetic Retinopathy Study (ETDRS) charts at simulated
20-feet distance. Low contrast sensitivity was measured using
Functional Acuity Contrast Test (FACT) charts at photopic
(85 cd) conditions at simulated 20 feet distance. FACT was
performed at 5 different spatial frequencies. Contrast
sensitivities were then combined as area under the curve (AUC)
over all spatial frequencies, as previously described.26 All tests
were performed monocularly for both eyes with habitual
refractive error correction. One VA measurement from 1 eye
and 3 FACT measurements from 3 eyes from 2 patients were
not included in the analysis due to time constrains or technical
issues.
Optical coherence tomography (OCT). Peripapillary retinal
nerve fiber layer thickness (pRNFL) and macular volume scans
were acquired with a Heidelberg Spectralis spectral-domain
OCT (Heidelberg Engineering, Heidelberg, Germany) as
previously described.27 pRNFL thickness was determined using
the device’s standard protocol from a 12° circular scan around the
optic nerve head with activated eye tracker. The maximum 100
averaging frames in the automatic real-time mode (ART) were
used whenever possible. Macular volume was acquired using a
custom protocol focusing on the fovea (61 vertical slices [B scans],
scanning angle of 30° 3 25°, resolution 768 A scans per B scan,
and ART 13). A second operator checked all scans for correct
centering, sufficient signal strength, and segmentation based on
the OSCAR-IB criteria.28 One patient had only 1 eye measured; 3
scans (2 pRNFL and 1 macular volume scan) from 3 patients, as
well as 2 pRNFL scans from 2 healthy controls, did not pass
quality control, leading to exclusion of these scans from data
analysis.
Intraretinal segmentation data were taken from beta software
(Heidelberg Eye Explorer V1.8.6.0 with Spectralis ViewingMod-
ule V6.0.0.2). This software automatically detects boundaries
between retinal layers. All automated segmentation results were
manually sighted and corrected where necessary by an experi-
enced grader. After the intraretinal segmentation, the ganglion
cell complex (GCC), consisting of retinal nerve fiber, ganglion
cell, and inner plexiform layers, the inner nuclear layer (INL),
the combined outer plexiform and nuclear layer (OPNL),
and the photoreceptor layer (PRL) were analyzed as volume
within the standard 6 mm ETDRS ring around the fovea.
Statistical analysis. Data are presented as mean 6 SD unless
otherwise noted. OCT and visual function measurements were
compared between patients with NMDAR encephalitis and
healthy controls using generalized estimating equation (GEE)
models with the respective OCT parameter from both eyes of
each subject as dependent variable and group (healthy controls vs
patients) as independent variable, correcting for age. GEE were
also used to analyze a potential visual function association with
mRS. Working correlation matrix was set to Exchangeable,
accounting for within-subject intereye correlations. Age
between groups was compared using a nonparametric Mann-
Whitney U test. Statistical significance was achieved at p ,
0.05. No previous sample size calculation was performed and
significance levels were not corrected for multiple comparisons.
The study should therefore be considered exploratory. All
statistical tests were performed with R Project 3.1.3 using
package geepack 1.2-0.29
RESULTS Thirty-one patients with NMDAR
encephalitis (28 female/3 male, mean age 28.7 6
8.9 years) were included in this study and compared
to matched healthy controls (28 female/3 male, 28.6
6 8.0 years). The sex match was exact; age did not
2 Neurology: Neuroimmunology & Neuroinflammation
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
differ between the groups (p5 0.889). Patients had a
median mRS of 1 (range 0–3). Seventeen patients
displayed no or only mild residual clinical impairment
(mRS 5 0 or 1), while 14 patients were clinically
impaired (mRS $ 2). A detailed description of the
mRS scores and treatment medication is given in
table 1.
VA was reduced in patients with NMDAR
encephalitis in comparison to matched healthy con-
trols (logMAR 0.02 6 0.14 vs 20.09 6 0.14, p ,
0.001; table 2 and figure 1). Moreover, FACT was
lower in patients (AUC 1.896 0.21 vs 2.006 0.26,
p 5 0.039; table 2 and figure 1). The mean scores of
all 5 spatial frequencies (A–E) in FACT testing were
decreased in patients compared to controls, but only
the 3 highest frequencies (C–E) reached significance
(A: p 5 0.263, B: p 5 0.404, C: p 5 0.029, D: p ,
0.001, E: p 5 0.014). Patients with no or only mild
clinical impairment (mRS 5 0 or 1, n 5 17) per-
formed better than patients with higher disability
(mRS $ 2, n 5 14) in high-contrast VA testing
(logMAR 20.02 6 0.11 vs 0.08 6 0.17; GEE
B 5 20.10, SE 5 0.05, p 5 0.030), but there was
no group difference in low-contrast FACT testing
(p 5 0.58).
Patients and controls did not differ in retinal layer
thickness measurements. Peripapillary RNFL, macu-
lar GCC, INL, OPNL, and PRL were all in the range
of matched healthy controls (table 2, figure 2).
The 2 patients with overlapping demyelinating
syndromes were not outliers in terms of high-
contrast VA testing (case 1: logMAR both eyes 5
0.1; case 2: logMAR right eye 5 0.1 and logMAR
left eye 5 20.1) or in terms of low-contrast VA
testing (case 1: AUC right eye 5 1.58 and AUC
left eye 5 1.17; case 2: AUC both eyes 5 2.15).
Furthermore, statistical testing for OCT parameter
differences remained negative after exclusion of
both patients with overlapping demyelinating syn-
dromes (data not shown).
DISCUSSION We report mild reduction of high-
and low-contrast VA in patients after NMDAR
encephalitis, which—although still in the range of
normative values—was lower than in matched
healthy controls. Importantly, more severely affected
patients had worse high-contrast VA than patients with
good clinical recovery. In contrast, we observed no
structural retinal damage.
This comprehensive assessment of visual func-
tion after NMDAR encephalitis complements
recent reports on visual dysfunction in affected pa-
tients.30–32 A case report described severely reduced
VA (20/125, right eye; 20/50, left eye) in a patient
with NMDAR encephalitis that gradually normal-
ized during recovery.32 This deficit was accompa-
nied by impaired higher-order visual functions, e.g.,
reduced color sensation and face recognition.
Impaired VA and optic neuritis were also reported
in patients with NMDAR encephalitis and overlap-
ping demyelinating syndromes.23,24 Interestingly,
antibodies to AQP4 and MOG were detected in
most of these patients in addition to NMDAR anti-
bodies. MOG antibodies were also found in a
patient who had developed optic neuritis with
optic disc swelling during NMDAR encephalitis
relapse.31 While these latter studies observed visual
impairment in patients with overlapping syn-
dromes, we here report impaired VA in isolated
NMDAR encephalitis without evidence of concom-
itant optic neuritis or other ophthalmic disease. On-
ly 2 patients presented with a demyelinating overlap
syndrome in our cohort, and both were seronegative
for AQP4 and MOG antibodies.
Given the normal-appearing retinal structure in
patients, we propose 2 candidate mechanisms for
Table 1 Detailed description of patients with
NMDA receptor encephalitis
Values
Modified Rankin Scale score
0 9
1 8
2 12
3 2
Delay between disease onset and study, mo
Mean 30.4
SD 21.1
Minimum 3.0
Maximum 82.0
Relapse
No 29
Yes 2
Immunosuppressive treatment (multiple
selections possible)
Steroids (IV) 28
Steroids (oral) 13
Immunoglobulins 15
Plasma exchange 16
Rituximab 7
Cyclophosphamide 5
Azathioprine 3
Immunoadsorption 2
Mycophenolate mofetil 1
Bortezomib 1
Chronic immunosuppression at study time
Methotrexate 2
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the underlying pathophysiology of the observed mild
visual function loss. First, as several retinal neuron
subtypes express NMDAR, the afferent visual system,
including the retina, might be affected directly.
mRNAs encoding NMDA subunits are expressed
predominantly in the inner retina.33 In the INL, hor-
izontal cells11,12 and amacrine cells express
NMDAR.13–16 Both cell types are interneurons,
which integrate signals from photoreceptors before
they are propagated to retinal ganglion cells. Moreover,
ganglion cells have been shown to express functional
NMDAR in several vertebrates.13,14,17–22 The above
studies suggest a role of NMDAR in orchestrating
the excitatory synapse and, more specifically, in mod-
ulating contrast sensitivity.10 In our study, all OCT
retinal layer measurements were similar in patients
and healthy controls, arguing against substantial struc-
tural damage or neurodegeneration of the retina. Argu-
ably, functional changes could also be based on
ultrastructural, synaptic alterations, which cannot be
detected with OCT. This is in line with cerebral
MRI analyses that show alterations of functional con-
nectivity despite normal routine imaging.8 OCT only
assesses retinal changes, but afferent visual system affec-
tion might reside anterograde, e.g., in the optic nerve,
optic radiation, or primary visual cortex. Retrograde
transsynaptic degeneration has been shown in diseases
such as multiple sclerosis, meaning that substantial
neurodegeneration would also present in the retina.34
Furthermore, a previous study employing structural
and functional resting-state MRI of patients after
NMDAR encephalitis did not report any macroscopic
alterations in the visual cortex.8
Second, the visual function deficit perhaps does not
result from alterations in the afferent visual pathway,
but at least in part from cortical processing deficits dur-
ing visual testing. The previously reported functional
and structural changes in patients after NMDAR
encephalitis that involve extensive white matter dam-
age support this hypothesis.8 Furthermore, a previous
study in patients with multiple sclerosis showed that
cognitive function impairment is associated with visual
test results beyond affection of the afferent visual path-
way.35 The difference between patients with no or mild
and those with existing residual clinical impairment
supports that this might be at least partially the case
in our study. Cognitive impairment might also influ-
ence test scores in other ways. For example, cognitively
impaired patients might be less likely to regularly
update refraction.
The study had several limitations. The visual sys-
tem assessments presented in this study were part of
a comprehensive test battery, including neuropsy-
chological testing and MRI.8,9 Due to the explora-
tory nature of this study, we were only able
to include high-contrast VA and low-contrast sen-
sitivity testing in addition to OCT and a basic
neuro-ophthalmologic examination. To confirm
Table 2 Optical coherence tomography and visual function measurements
NMDAR-E HC GEE
Mean SD Min Max Mean SD Min Max B SE p Value
VA, logMAR 0.02 0.14 20.2 0.5 20.09 0.14 20.2 0.5 0.12 0.03 ,0.001
FACT, AUC 1.89 0.21 1.24 2.20 2.00 0.26 0.67 2.28 20.11 0.05 0.039
pRNFL, mm 99.0 8.4 85.0 115.0 99.9 9.2 79.0 120.0 20.73 2.14 0.73
GCC, mm3 2.91 0.18 2.55 3.37 2.95 0.20 2.54 3.44 20.04 0.05 0.40
INL, mm3 0.95 0.05 0.82 1.07 0.95 0.05 0.82 1.05 20.005 0.012 0.70
OPNL, mm3 2.55 0.17 2.20 2.84 2.55 0.16 2.18 2.89 20.01 0.04 0.87
PRL, mm3 2.24 0.05 2.10 2.35 2.24 0.06 2.12 2.37 0.004 0.013 0.75
Abbreviations: AUC 5 area under the curve; B 5 coefficient; FACT 5 Functional Acuity Contrast Test; GCC 5 ganglion cell
complex; GEE 5 generalized estimation equation models; HC 5 healthy controls; INL 5 inner nuclear layer; NMDAR-E 5
NMDA receptor encephalitis; OPNL 5 outer plexiform and nuclear layer; PRL 5 photoreceptor layer; pRNFL 5 peripapillary
retinal nerve fiber layer; VA 5 visual acuity.
Figure 1 Visual acuity differences
(A) Visual acuity measured according to Early Treatment Diabetic Retinopathy Study charts
and (B) low contrast sensitivity tested using Functional Acuity Contrast Test (FACT) charts
at photopic (85 cd) conditions compared between healthy controls (HC) and patients with
NMDA receptor encephalitis (NMDAR-E). Each dot represents 1 eye.
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and further elucidate the results of the study, elec-
trophysiologic assessment of the optic nerve, tract,
and radiation, as well as from the retina, would be
necessary. Study participants only used habitual
correction. As a result, we cannot rule out a poten-
tial bias introduced by insufficient refractory error
correction. However, data distribution of high- and
low-contrast FACT measurements and the reduc-
tion of all 5 spatial frequencies in low-contrast test-
ing suggests that a potential refractory error bias
could not sufficiently explain observed group differ-
ences. For low-contrast VA, further studies are
needed to determine the extent to which deficits
are caused either by high-contrast acuity deficits
or affection of low-contrast visual perception. None
of the patients reported visual dysfunction, and the
reported mild VA deficits seem not to be relevant
for an individual patient and instead were only sta-
tistically significant in a group comparison. The
clinical relevance of visual function deficits—
beyond insight into the pathophysiology of the
disease—therefore remains to be investigated.
In this study, we present preliminary evidence
for visual dysfunction in patients recovering from
NMDAR encephalitis. These functional changes
were not based on detectable structural damage
using OCT. The association between visual func-
tion and residual disability indicates that visual
function may provide insight into general disease
processes in NMDAR encephalitis. Potentially,
visual function examination may provide informa-
tion to the clinician about underlying changes in
disease activity when performed longitudinally.
Therefore, clarifying the clinical significance of
visual dysfunction in NMDAR encephalitis war-
rants further investigation, including in longitudi-
nal studies. Additionally, future studies should
include electroretinography to assess potential func-
tional retinal alterations.
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